Details for This Review

Study Population: Adults hospitalized with moderate to severe COVID-19 treated with remdesivir, placebo, or standard care

Efficacy End Points: All-cause mortality and need for respiratory support (high-flow oxygen, noninvasive or invasive ventilation) at up to 28 days of treatment, duration of invasive mechanical ventilation, quality of life, duration of hospitalization, intensive care unit (ICU) admission, and duration of ICU stay

Harm End Points: Any adverse event at up to 28 days of treatment

Narrative: SARS-CoV-2 has infected more than 300 million people and caused more than 5.5 million deaths worldwide.¹ There has been an urgency to identify effective treatments, including antiviral medications, to decrease morbidity and mortality. Remdesivir is an antiviral drug that has been hypothesized to inhibit viral replication of RNA viruses such as SARS-CoV-2.²